-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NasdaqUSDISIN US45257L1089
ISIN US45257L1089
WKN A2H8YL
Symbol IMMP
Währung
USD
Börse
Nasdaq Zeitzone: America/New_York
Firmenname
Immutep Limited
Marktkapitalisierung
199.181.320 (+- 21%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
156.362.640 oder 242.000.000
EBITDA 0
PEGRatio None
Buchwert 0.8
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 3,9 EUR +14,70%
Dir gefallen die Informationen zu Immutep Ltd ADR?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Immutep Ltd ADR?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Immutep Ltd ADR?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Immutep Ltd ADR?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
40 News & Informationen zur Immutep Ltd ADR Aktie
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs for ASX health stocks.
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
Sydney, Sept. 01, 2021 (GLOBE NEWSWIRE) — Last 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patient has been enrolled and safely…
Immutep : PRELIMINARY FINAL REPORT (Form 6-K)
Phase II
TACTI-002 is Immutep's Phase II study evaluating the combination of efti with KEYTRUDA® in up to 183 patients with non-small cell lung cancer in 1st and 2nd line … | September 1, 2021
7% Gain for Immutep Shares as it Progresses Clinical Trials (ASX:IMM)
Small-cap biotech stock Immutep (ASX:IMM) is on the up today. Shares are currently trading 7.92% higher at time of writing. Climbing higher thanks to some positive news in relation to the company’s ongoing clinical trials.
Immutep : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002
ASX/Media Release
Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients
in TACTI-002
… | September 1, 2021
Immutep (ASX:IMM) enrols final patient in lung cancer trial
Biotech company Immutep (ASX:IMM) enrols its last patient in its trial on non-small cell lung cancer patients.
ASX Health Stocks: Memphasys jumps on legal settlement after flaw with its Felix sperm-separating device
ASX Health Stocks: Memphasys jumps on legal settlement after flaw with its Felix sperm-separating device
Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) — SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (” Immutep” or the ” Company”) is
Immutep’s (ASX:IMM) partner, EOC Pharma, expands efti trial pipeline
Immutep's (IMM) China-based partner, EOC Pharma (ASX:EOC), has announced plans to expand its clinical trial pipeline for eftilagimod alpha (efti).
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. Is there a place for CAR-T therapy in the market?
IMMUTEP : ANNOUNCES CHINESE PATENT GRANT FOR LAG-3 ANTAGONIST ANTIBODY LAG525 (Form 6-K)
IMMUTEP ANNOUNCES CHINESE PATENT GRANT FOR
LAG-3 ANTAGONIST ANTIBODY LAG525
SYDNEY, AUSTRALIA – 27 August 2021 -Immutep Limited , is… | August 27, 2021
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) — SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is…
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
Closing Bell: ASX closes slightly lower, still notches up weekly gain
Closing Bell: ASX closes slightly lower, still notches up weekly gain
Market Highlights and 5 ASX Small Caps to watch on Friday
ASX small caps to watch on Wednesday 21 July, and highlights from Wall Street overnight. ASX stocks to watch include MGC Pharma and Ausbank.
Immutep (ASX:IMM) granted Chinese patent for anti-LAG-3 antibody
Immutep (ASX:IMM) has been granted its fifth patent, with China as the newest office to accept its submission.
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Trading Places: Who’s betting on return to office stocks?
ASX fund managers are buying return to office stocks such as ServCorp (ASX:SRV) which operates services offices and is tipping people will return.
Immutep Reports Dosing Of First Patient For Triple Combination (efti Anti-PD-1 Chemo) In INSIGHT-003
Sydney, Aug. 05, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (” Immutep” or the ” Company”), a biotechnology company developing novel
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
Micro cap medical device company dorsaVi (DVL) took the limelight this morning, jumping by 15% after saying that it has extended the contract with Medtronic
Why the Immutep (ASX:IMM) share price is charging higher today
The Immutep (ASX: IMM) share price is charging up in morning trade today. We take a look at the ASX healthcare company's latest update.
Market Highlights and 5 ASX Small Caps to watch on Thursday
ASX small caps to watch on Thursday 5 August, and highlights from Wall Street overnight. ASX stocks include Immutep (IMM), Neuren Pharma (NEU).
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing
ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the benchmark rose by 3%.
Immutep : Results of EGM
26 July 2021
ASX Market Announcements Office
ASX Limited
20 Bridge Street SYDNEY NSW… | July 26, 2021
ASX health stocks: HitIQ leaps 5% after deal to trial junior rugby players with concussion technology
ASX health stocks rose 1.5%, compared with the broader index which rose by 1.4%, helped by brain injury specialist, HitIQ (ASX:HIQ) which rose by 5.5%.
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Immutep Quarterly Activities Report
Immutep entered late-stage development in the newly validated LAG-3 space
Data from 1st line NSCLC and 2nd line HNSCC presented at ASCO
Efti to be
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
We reveal the 5 best performing ASX healthcare shares in the last financial year. You might be surprised with the companies that make the list
Immutep Receives FDA And IRB Approval In The US For Phase IIb TACTI-003 Trial In HNSCC
Sydney, July 06, 2021 (GLOBE NEWSWIRE) — ASX/Media Release
Regulatory steps completed with the competent authority (FDA) and institutional review board
The clinical ambitions of these two ASX biotechs just got a boost from the FDA
Opthea (ASX:OPT) and Immutep (ASX:IMM) received Fast Track Designation and approval for their next planned clinical trials.
Immutep (ASX:IMM) to begin Phase IIb head and neck cancer study
Immutep (ASX:IMM) has completed all regulatory steps to commence its Phase IIb head and neck cancer trial, TACTI-003, in the United States.
Slayback Appoints Pete Meyers As Chief Financial Officer
PRINCETON, N.J., June 25, 2021 /PRNewswire/ — Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of
Check Up: From Moderna’s effective jabs to Patrys’ brain cancer breakthrough
Stockhead reports ASX biotech and healthcare roundup for the last fortnight. Stocks include Actinogen (ACW), Suda Pharma (SUD), and Patrys (PAB).
Should I Avoid Lyra Therapeutics, Inc. (LYRA)?
In this article we will take a look at whether hedge funds think Lyra Therapeutics, Inc. (NASDAQ:LYRA) is a good investment right now. We check hedge…
Immutep Completes A A$60 Million Placement To Expand Its Clinical Development And Manufacturing Program Into Late-Stage Settings
Sydney, AUSTRALIA, June 21, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( I mmutep or C ompany), is pleased to announce that it has
Immutep To Evaluate Efti In Triple Combination Therapy Phase I Study With Chemotherapy And An Anti-PD-1 Therapy
New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours
Expands the evaluation of efti into a triple combination therapy of
ASX Small Cap Lunch Wrap: Don’t say vol… I said voool… vooooool
Giddy up, because the liquidity assumptions underpinning post-COVID markets appear to have had their first little test.
Why the Immutep (ASX:IMM) share price is sinking 16% today
The Immutep Ltd (ASX:IMM) share price is under pressure and sinking notably lower on Monday. Here's why its shares are down 16%…
Immutep (ASX:IMM) to begin efti trial, launches $60m placement
Immutep (ASX:IMM) will begin a phase one trial to evaluate its efti product in conjunction with chemotherapy and an anti-PD-1 therapy.
10 at 10: These ASX stocks are running wild this morning
10 at 10: These ASX stocks are running wild this morning